sulfadiazine
RxCUI 10171
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Sulfadiazine
Sulfadiazine is an antibiotic. Used together with pyrimethamine, a dihydrofolate reductase inhibitor, it is the treatment of choice for toxoplasmosis, which is caused by a protozoan parasite. It is a second-line treatment for otitis media, prophylaxis of rheumatic fever, chancroid, chlamydia, and infections by Haemophilus influenzae. It is also used as adjunct therapy for chloroquine-resistant malaria and several forms of bacterial meningitis. It is taken by mouth. Sulfadiazine is available in multiple generic tablets of 500 mg. For urinary tract infections, the usual dose is 4 to 6 grams daily in 3 to 6 divided doses. Common side effects include nausea, diarrhea, headache, fever, rash, depression, and pancreatitis. It should not be used in people who have severe liver problems, kidney problems, or porphyria. If used during pregnancy, it may increase the risk of kernicterus in the baby. While the company that makes it does not recommend use during breastfeeding, use is believed to be safe if the baby is otherwise healthy. It is in the sulfonamide class of medications. Sulfadiazine was approved for medical use in the United States in 1941. It is on the World Health Organization's List of Essential Medicines. Sulfadiazine is available as a generic medication.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Conditions being studied
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.